JP2010521534A - 黄斑変性を処置するためのマスクまたはコーティング銅塩の使用 - Google Patents
黄斑変性を処置するためのマスクまたはコーティング銅塩の使用 Download PDFInfo
- Publication number
- JP2010521534A JP2010521534A JP2010500223A JP2010500223A JP2010521534A JP 2010521534 A JP2010521534 A JP 2010521534A JP 2010500223 A JP2010500223 A JP 2010500223A JP 2010500223 A JP2010500223 A JP 2010500223A JP 2010521534 A JP2010521534 A JP 2010521534A
- Authority
- JP
- Japan
- Prior art keywords
- copper
- mask
- copper salt
- capsule material
- coated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001879 copper Chemical class 0.000 title claims abstract description 44
- 208000002780 macular degeneration Diseases 0.000 title claims description 8
- 239000000203 mixture Substances 0.000 claims abstract description 30
- 239000010949 copper Substances 0.000 claims abstract description 24
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229910052802 copper Inorganic materials 0.000 claims abstract description 22
- 150000001875 compounds Chemical class 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 11
- 230000015556 catabolic process Effects 0.000 claims abstract description 8
- 238000006731 degradation reaction Methods 0.000 claims abstract description 8
- 108010010803 Gelatin Proteins 0.000 claims abstract description 4
- 229920000159 gelatin Polymers 0.000 claims abstract description 4
- 239000008273 gelatin Substances 0.000 claims abstract description 4
- 235000019322 gelatine Nutrition 0.000 claims abstract description 4
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 4
- 239000002502 liposome Substances 0.000 claims abstract description 3
- 239000002775 capsule Substances 0.000 claims description 23
- 239000000463 material Substances 0.000 claims description 21
- 235000015872 dietary supplement Nutrition 0.000 claims description 20
- 238000000576 coating method Methods 0.000 claims description 12
- 239000011248 coating agent Substances 0.000 claims description 11
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims description 11
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 10
- 229940012843 omega-3 fatty acid Drugs 0.000 claims description 9
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 8
- 239000006014 omega-3 oil Substances 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 6
- 229930003427 Vitamin E Natural products 0.000 claims description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 4
- GEZOTWYUIKXWOA-UHFFFAOYSA-L copper;carbonate Chemical compound [Cu+2].[O-]C([O-])=O GEZOTWYUIKXWOA-UHFFFAOYSA-L 0.000 claims description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 4
- 150000003904 phospholipids Chemical class 0.000 claims description 4
- 230000000087 stabilizing effect Effects 0.000 claims description 4
- 235000019165 vitamin E Nutrition 0.000 claims description 4
- 229940046009 vitamin E Drugs 0.000 claims description 4
- 239000011709 vitamin E Substances 0.000 claims description 4
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical group [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 claims description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 3
- 229930003268 Vitamin C Natural products 0.000 claims description 3
- 229940116318 copper carbonate Drugs 0.000 claims description 3
- 229940108925 copper gluconate Drugs 0.000 claims description 3
- 230000001419 dependent effect Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims description 3
- 235000019154 vitamin C Nutrition 0.000 claims description 3
- 239000011718 vitamin C Substances 0.000 claims description 3
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 2
- QPLDLSVMHZLSFG-UHFFFAOYSA-N Copper oxide Chemical compound [Cu]=O QPLDLSVMHZLSFG-UHFFFAOYSA-N 0.000 claims description 2
- 239000005751 Copper oxide Substances 0.000 claims description 2
- 229920000858 Cyclodextrin Polymers 0.000 claims description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 2
- 235000010376 calcium ascorbate Nutrition 0.000 claims description 2
- 229940047036 calcium ascorbate Drugs 0.000 claims description 2
- 239000011692 calcium ascorbate Substances 0.000 claims description 2
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 claims description 2
- 229940106189 ceramide Drugs 0.000 claims description 2
- 150000001783 ceramides Chemical class 0.000 claims description 2
- 229910000431 copper oxide Inorganic materials 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 2
- 235000012680 lutein Nutrition 0.000 claims description 2
- 229960005375 lutein Drugs 0.000 claims description 2
- 239000001656 lutein Substances 0.000 claims description 2
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims description 2
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 229940042585 tocopherol acetate Drugs 0.000 claims description 2
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims description 2
- 239000011701 zinc Substances 0.000 claims description 2
- 229910052725 zinc Inorganic materials 0.000 claims description 2
- 239000011787 zinc oxide Substances 0.000 claims description 2
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 claims 1
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 claims 1
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 claims 1
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 claims 1
- 229940079721 copper chloride Drugs 0.000 claims 1
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 claims 1
- 229960004643 cupric oxide Drugs 0.000 claims 1
- 230000001079 digestive effect Effects 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
- 235000010930 zeaxanthin Nutrition 0.000 claims 1
- 239000001775 zeaxanthin Substances 0.000 claims 1
- 229940043269 zeaxanthin Drugs 0.000 claims 1
- 239000011257 shell material Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 3
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 3
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 3
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 3
- 239000008393 encapsulating agent Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 description 2
- 235000021294 Docosapentaenoic acid Nutrition 0.000 description 2
- OPGOLNDOMSBSCW-CLNHMMGSSA-N Fursultiamine hydrochloride Chemical compound Cl.C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N OPGOLNDOMSBSCW-CLNHMMGSSA-N 0.000 description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- -1 cyclodextrin compound Chemical class 0.000 description 2
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- IQLUYYHUNSSHIY-HZUMYPAESA-N eicosatetraenoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C=C\C=C\C(O)=O IQLUYYHUNSSHIY-HZUMYPAESA-N 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000000873 masking effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- JIWBIWFOSCKQMA-UHFFFAOYSA-N stearidonic acid Natural products CCC=CCC=CCC=CCC=CCCCCC(O)=O JIWBIWFOSCKQMA-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- 229910000009 copper(II) carbonate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- OMZSGWSJDCOLKM-UHFFFAOYSA-N copper(II) sulfide Chemical compound [S-2].[Cu+2] OMZSGWSJDCOLKM-UHFFFAOYSA-N 0.000 description 1
- 239000011646 cupric carbonate Substances 0.000 description 1
- 235000019854 cupric carbonate Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 229940076783 lucentis Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- YTZALCGQUPRCGW-ZSFNYQMMSA-N verteporfin Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(CCC(=O)OC)=C(C)C(N3)=C3)=N2)C)=C(C=C)C(C)=C1C=C1C2=CC=C(C(=O)OC)[C@@H](C(=O)OC)[C@@]2(C)C3=N1 YTZALCGQUPRCGW-ZSFNYQMMSA-N 0.000 description 1
- 229940061392 visudyne Drugs 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P20/00—Coating of foodstuffs; Coatings therefor; Making laminated, multi-layered, stuffed or hollow foodstuffs
- A23P20/10—Coating with edible coatings, e.g. with oils or fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/30—Copper compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nanotechnology (AREA)
- Diabetes (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Botany (AREA)
- Biophysics (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07104792A EP1974733A1 (en) | 2007-03-23 | 2007-03-23 | Use of a masked or coated copper salt for the treatment of macular degeneration |
| EP07111322 | 2007-06-28 | ||
| PCT/EP2008/053283 WO2008116806A1 (en) | 2007-03-23 | 2008-03-19 | Use of a masked or coated copper salt for the treatment of macular degeneration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010521534A true JP2010521534A (ja) | 2010-06-24 |
| JP2010521534A5 JP2010521534A5 (enExample) | 2011-05-12 |
Family
ID=39477329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010500223A Pending JP2010521534A (ja) | 2007-03-23 | 2008-03-19 | 黄斑変性を処置するためのマスクまたはコーティング銅塩の使用 |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20080233182A1 (enExample) |
| EP (1) | EP2124973B1 (enExample) |
| JP (1) | JP2010521534A (enExample) |
| KR (1) | KR101688656B1 (enExample) |
| AR (1) | AR065791A1 (enExample) |
| AU (1) | AU2008231847B2 (enExample) |
| BR (1) | BRPI0809258B8 (enExample) |
| CA (1) | CA2681514C (enExample) |
| CL (1) | CL2008000804A1 (enExample) |
| CO (1) | CO6230993A2 (enExample) |
| DK (1) | DK2124973T3 (enExample) |
| EC (1) | ECSP099700A (enExample) |
| ES (1) | ES2542694T3 (enExample) |
| GT (1) | GT200900251A (enExample) |
| IL (1) | IL201109A (enExample) |
| MA (1) | MA31293B1 (enExample) |
| MX (1) | MX2009010244A (enExample) |
| MY (1) | MY164520A (enExample) |
| NZ (1) | NZ579852A (enExample) |
| PE (1) | PE20090186A1 (enExample) |
| PL (1) | PL2124973T3 (enExample) |
| PT (1) | PT2124973E (enExample) |
| RU (1) | RU2009139002A (enExample) |
| TN (1) | TN2009000387A1 (enExample) |
| TW (1) | TW200904456A (enExample) |
| WO (1) | WO2008116806A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022533731A (ja) * | 2019-05-22 | 2022-07-25 | バイエル・コンシューマー・ケア・アクチェンゲゼルシャフト | アスコルビン酸塩の形態のビタミンcを含む、ビタミンおよびミネラルのソフトゲルカプセル調製物 |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010222648B2 (en) | 2009-03-09 | 2016-07-07 | Pronova Biopharma Norge As | Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof |
| KR101759255B1 (ko) | 2015-09-18 | 2017-07-18 | 한국산업기술대학교산학협력단 | 무촉매 방식 가변경사각을 갖는 나노 구조물 성장 방법 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5298237A (en) * | 1992-01-24 | 1994-03-29 | The Trustees Of Columbia University In The City Of New York | Gel composition for reduction of gingival inflammation and retardation of dental plaque |
| JPH11502838A (ja) * | 1995-03-29 | 1999-03-09 | ザ、プロクター、エンド、ギャンブル、カンパニー | キサンチン誘導体を含むゼラチン外殻を有するソフトゼラチンカプセル |
| US20030104043A1 (en) * | 2001-12-03 | 2003-06-05 | Brown Beverly Ann | Topical cream for alleviating spider veins |
| US20050249821A1 (en) * | 2004-05-08 | 2005-11-10 | Paul Edward L Jr | Nutritional supplement for treatment of ocular diseases |
| WO2006017179A1 (en) * | 2004-07-09 | 2006-02-16 | Robert Sabin | Compositions and methods of use for treatment of mammalian diseases |
| WO2006055965A2 (en) * | 2004-11-19 | 2006-05-26 | Martek Biosciences Corporation | Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2043487A1 (enExample) * | 1969-05-28 | 1971-02-19 | Commissariat Energie Atomique | |
| US20030004043A1 (en) * | 2001-06-27 | 2003-01-02 | Deola James A. | Pivoting backrest for exercise apparatus |
| US20050249820A1 (en) * | 2004-05-04 | 2005-11-10 | Akorn, Inc. | Nutritional supplement for the treatment and prevention of macular degeneration |
| US7449196B2 (en) * | 2004-07-09 | 2008-11-11 | Robert Sabin | Anti tumor compositions and methods of use |
-
2008
- 2008-03-19 PL PL08718009T patent/PL2124973T3/pl unknown
- 2008-03-19 ES ES08718009.7T patent/ES2542694T3/es active Active
- 2008-03-19 NZ NZ579852A patent/NZ579852A/en not_active IP Right Cessation
- 2008-03-19 PE PE2008000520A patent/PE20090186A1/es not_active Application Discontinuation
- 2008-03-19 AU AU2008231847A patent/AU2008231847B2/en active Active
- 2008-03-19 KR KR1020097022078A patent/KR101688656B1/ko active Active
- 2008-03-19 PT PT87180097T patent/PT2124973E/pt unknown
- 2008-03-19 EP EP08718009.7A patent/EP2124973B1/en active Active
- 2008-03-19 MY MYPI20093944A patent/MY164520A/en unknown
- 2008-03-19 JP JP2010500223A patent/JP2010521534A/ja active Pending
- 2008-03-19 RU RU2009139002/15A patent/RU2009139002A/ru not_active Application Discontinuation
- 2008-03-19 WO PCT/EP2008/053283 patent/WO2008116806A1/en not_active Ceased
- 2008-03-19 DK DK08718009.7T patent/DK2124973T3/da active
- 2008-03-19 BR BRPI0809258A patent/BRPI0809258B8/pt active IP Right Grant
- 2008-03-19 MX MX2009010244A patent/MX2009010244A/es not_active Application Discontinuation
- 2008-03-19 AR ARP080101138A patent/AR065791A1/es not_active Application Discontinuation
- 2008-03-19 CA CA2681514A patent/CA2681514C/en active Active
- 2008-03-20 US US12/052,016 patent/US20080233182A1/en not_active Abandoned
- 2008-03-20 CL CL200800804A patent/CL2008000804A1/es unknown
- 2008-03-21 TW TW097110250A patent/TW200904456A/zh unknown
-
2009
- 2009-09-22 IL IL201109A patent/IL201109A/en active IP Right Grant
- 2009-09-22 GT GT200900251A patent/GT200900251A/es unknown
- 2009-09-22 TN TNP2009000387A patent/TN2009000387A1/fr unknown
- 2009-09-23 CO CO09103873A patent/CO6230993A2/es not_active Application Discontinuation
- 2009-10-02 MA MA32248A patent/MA31293B1/fr unknown
- 2009-10-23 EC EC2009009700A patent/ECSP099700A/es unknown
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5298237A (en) * | 1992-01-24 | 1994-03-29 | The Trustees Of Columbia University In The City Of New York | Gel composition for reduction of gingival inflammation and retardation of dental plaque |
| JPH11502838A (ja) * | 1995-03-29 | 1999-03-09 | ザ、プロクター、エンド、ギャンブル、カンパニー | キサンチン誘導体を含むゼラチン外殻を有するソフトゼラチンカプセル |
| US20030104043A1 (en) * | 2001-12-03 | 2003-06-05 | Brown Beverly Ann | Topical cream for alleviating spider veins |
| US20050249821A1 (en) * | 2004-05-08 | 2005-11-10 | Paul Edward L Jr | Nutritional supplement for treatment of ocular diseases |
| WO2006017179A1 (en) * | 2004-07-09 | 2006-02-16 | Robert Sabin | Compositions and methods of use for treatment of mammalian diseases |
| WO2006055965A2 (en) * | 2004-11-19 | 2006-05-26 | Martek Biosciences Corporation | Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same |
Non-Patent Citations (2)
| Title |
|---|
| JPN5010007784; BOSE,P.K. et al: CARBOHYDRATE RESEARCH Vol.323, No.1-4, 19990112, p.63-72, ELSEVIER SCIENTIFIC PUBLISHING COMPANY * |
| JPN6013016498; 岡野定輔: 新・薬剤学総論 改訂第3版, 1987, p.143, 144, 南江堂 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022533731A (ja) * | 2019-05-22 | 2022-07-25 | バイエル・コンシューマー・ケア・アクチェンゲゼルシャフト | アスコルビン酸塩の形態のビタミンcを含む、ビタミンおよびミネラルのソフトゲルカプセル調製物 |
| JP7536045B2 (ja) | 2019-05-22 | 2024-08-19 | バイエル・コンシューマー・ケア・アクチェンゲゼルシャフト | アスコルビン酸塩の形態のビタミンcを含む、ビタミンおよびミネラルのソフトゲルカプセル調製物 |
Also Published As
| Publication number | Publication date |
|---|---|
| DK2124973T3 (da) | 2015-06-22 |
| AR065791A1 (es) | 2009-07-01 |
| KR20100015799A (ko) | 2010-02-12 |
| US20080233182A1 (en) | 2008-09-25 |
| EP2124973A1 (en) | 2009-12-02 |
| MA31293B1 (fr) | 2010-04-01 |
| WO2008116806A1 (en) | 2008-10-02 |
| RU2009139002A (ru) | 2011-04-27 |
| KR101688656B1 (ko) | 2016-12-21 |
| MY164520A (en) | 2017-12-29 |
| AU2008231847A1 (en) | 2008-10-02 |
| ECSP099700A (es) | 2009-11-30 |
| PE20090186A1 (es) | 2009-03-20 |
| CA2681514C (en) | 2016-11-08 |
| BRPI0809258B1 (pt) | 2019-10-01 |
| PT2124973E (pt) | 2015-09-01 |
| BRPI0809258A2 (pt) | 2014-09-23 |
| BRPI0809258B8 (pt) | 2021-05-25 |
| CL2008000804A1 (es) | 2008-10-24 |
| EP2124973B1 (en) | 2015-05-27 |
| ES2542694T3 (es) | 2015-08-10 |
| CO6230993A2 (es) | 2010-12-20 |
| TW200904456A (en) | 2009-02-01 |
| CA2681514A1 (en) | 2008-10-02 |
| MX2009010244A (es) | 2009-10-26 |
| TN2009000387A1 (en) | 2010-12-31 |
| IL201109A (en) | 2016-10-31 |
| AU2008231847B2 (en) | 2012-12-06 |
| NZ579852A (en) | 2012-03-30 |
| PL2124973T3 (pl) | 2015-10-30 |
| IL201109A0 (en) | 2010-05-17 |
| GT200900251A (es) | 2018-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9012501B2 (en) | Type A gelatin capsule containing PUFA in free acid form | |
| AU2018202316B2 (en) | A pharmaceutical composition | |
| JP2010521534A (ja) | 黄斑変性を処置するためのマスクまたはコーティング銅塩の使用 | |
| JP2010521534A5 (enExample) | ||
| TW201000027A (en) | Organic compounds | |
| CN101668533A (zh) | 被掩蔽或包涂的铜盐在治疗黄斑变性中的用途 | |
| EA046793B1 (ru) | Применение композиции (варианты) для профилактического или терапевтического лечения кальцификации сосудов |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110318 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110318 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130416 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130924 |